zosuquidar
Sign in to saveAlso known as LSM-5782
Zosuquidar (development code LY-335979) is an experimental antineoplastic drug. Zosquidir inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.
~4 min read
Encyclopedic overview
2 sectionsContents
- Synthesis
- References
{{Drugbox | Verifiedfields = changed | verifiedrevid = 477869670 | IUPAC_name = (2R)-1-{4-[(1aR,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl}-3-(quinolin-5-yloxy)propan-2-ol | image = Zosuquidar.svg | image_class = skin-invert-image | width = 200px
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration =
Excerpted from Wikipedia’s “zosuquidar” article, available under the CC BY-SA 4.0 licence.